Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Fagioli, Franca  [Clear All Filters]
2024
Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Brüggemann M, Mejstrikova E, Cazzaniga G, Hrusak O, Szczepanowski M, et al. CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment. Blood. 2024.
Sharma A, Galimard J-E, Pryce A, Bhoopalan SVelan, Dalissier A, Dalle J-H, Locatelli F, Jubert C, Mirci-Danicar O, Kitra-Roussou V, et al. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study. Bone Marrow Transplant. 2024.
Pellegrino F, Tirtei E, Divincenzo F, Campello A, Rubino C, Augustoni E, Linari A, Asaftei SDorin, Fagioli F. An integrative morpho-molecular approach in malignant ectomesenchymoma diagnosis: report of a new paediatric case and a review of the literature. Front Oncol. 2024;14:1320541.
Saglio F, Pagliara D, Zecca M, Balduzzi A, Cattoni A, Prete A, Tambaro FPaolo, Faraci M, Calore E, Locatelli F, et al. Long-term complications after allogeneic hematopoietic stem cell transplantation for pediatric patients with acute leukemia or myelodysplastic syndrome given either a Treosulfan- or a Busulfan-based conditioning regimen: results of an AIEOP (Associazione . Transplant Cell Ther. 2024.
Prete A, Lanino E, Saglio F, Biffi A, Calore E, Faraci M, Rondelli R, Favre C, Zecca M, Casazza G, et al. Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Children with High-Risk Neuroblastoma Using a Reduced-Intensity Conditioning Regimen: Results from the AIEOP trial. Transplant Cell Ther. 2024.
2023
De Marchi F, Mareschi K, Ferrero I, Cantello R, Fagioli F, Mazzini L. Effect of mesenchymal stromal cell transplantation on long-term survival in amyotrophic lateral sclerosis. Cytotherapy. 2023.
Spadea M, Saglio F, Ceolin V, Barone M, Zucchetti G, Quarello P, Fagioli F. Immune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment. Eur J Pediatr. 2023.
Sykora K-W, Beier R, Schulz A, Cesaro S, Greil J, Goździk J, Sedlacek P, Bader P, Schulte J, Zecca M, et al. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2023.
2022
Berger M, Barone M, Spadea M, Saglio F, Pessolano R, Fagioli F. HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients. Pediatr Transplant. 2022:e14233.
2021
Felicetti F, Aimaretti E, Dal Bello F, Gatti F, Godono A, Saba F, Einaudi G, Collino M, Fagioli F, Aragno M, et al. Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications. Free Radic Biol Med. 2021.
2020
Berger M, Faraci M, Saglio F, Giardino S, Vassallo EErnestina, Prete A, Fagioli F. CD34+ selected peripheral blood Stem Cell Boost (SCB) for Poor Graft Function (PGF) or mixed chimerism in pediatric patients, after hematopoietic stem cell transplantation: Results of a retrospective multicenter study. Pediatr Transplant. 2020:e13909.
Felicetti F, Castiglione A, Biasin E, Fortunati N, Dionisi-Vici M, Matarazzo P, Ciccone G, Fagioli F, Brignardello E. Effects of treatments on gonadal function in long-term survivors of pediatric hematologic malignancies: A cohort study. Pediatr Blood Cancer. 2020:e28709.
Masetti R, Vendemini F, Quarello P, Girardi K, Prete A, Fagioli F, Pession A, Locatelli F. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children. Pediatr Blood Cancer. 2020:e28208.
Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti M-C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Willasch AManfred, Peters C, Sedlacek P, Dalle J-H, Kitra-Roussou V, Yeşilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AAli, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020.
Kalwak K, Mielcarek M, Patrick K, Styczyński J, Bader P, Corbacioglu S, Burkhardt B, Sykora KWalter, Drabko K, Goździk J, et al. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplant. 2020.
2019
Peccatori J, Mastaglio S, Giglio F, Greco R, Crocchiolo R, Patriarca F, Forno B, Deola S, Assanelli A, Stanghellini MTeresa Lup, et al. Clofarabine and Treosulfan as conditioning for matched related and unrelated HSCT: results from the phase II trial "Clo3o". Biol Blood Marrow Transplant. 2019.
Morandi E, Cereda M, Incarnato D, Parlato C, Basile G, Anselmi F, Lauria A, Simon LMarie, Polignano ILaurence, Arruga F, et al. HaTSPiL: A modular pipeline for high-throughput sequencing data analysis. PLoS One. 2019;14(10):e0222512.
Mareschi K, Montanari P, Rassu M, Galliano I, Daprà V, Adamini A, Castiglia S, Fagioli F, Bergallo M. Human Endogenous Retrovirus-H and K Expression in Human Mesenchymal Stem Cells as Potential Markers of Stemness. Intervirology. 2019:1-6.
Bagnasco F, Caruso S, Andreano A, Valsecchi MGrazia, Jankovic M, Biondi A, Miligi L, Casella C, Terenziani M, Massimino M, et al. Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry. Eur J Cancer. 2019;110:86-97.
Rossi F, Coppo M, Zucchetti G, Ricci F, Fagioli F. A new frontier of pediatric oncology rehabilitation: Establishment of a dedicated working-group within the Italian association of pediatric hematology and oncology. J Pediatr Rehabil Med. 2019.
2015
Bergallo M, Galliano I, Montanari P, Gambarino S, Mareschi K, Ferro F, Fagioli F, Tovo P-A, Ravanini P. CMV induces HERV-K and HERV-W expression in kidney transplant recipients. J Clin Virol. 2015;68:28-31.
2013
Boye K, Del Prever ABrach, Eriksson M, Saeter G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S, Hall KSundby. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. Pediatr Blood Cancer. 2013.